HIV and Kidney Transplants: Navigating the Complexities of SRTR Data
"Explore the insights and limitations of using Scientific Registry of Transplant Recipients (SRTR) data to improve outcomes for HIV-positive kidney transplant recipients."
In a recent issue of the American Journal of Transplantation (AJT), Sawinski et al. delved into the impact of combined antiretroviral therapy (cART) on kidney transplant outcomes in HIV-infected recipients. Their analysis, which utilized the Scientific Registry of Transplant Recipients (SRTR) data linked to IMS pharmacy refills, revealed critical insights into the role of protease inhibitors (PI) in transplant success.
The study highlighted a concerning trend: cART regimens based on protease inhibitors (PI) appeared to have a detrimental effect on patient and graft survival. This finding raises important questions about the complexities of managing HIV-positive recipients undergoing kidney transplantation.
While the reasons behind these poorer outcomes remain unclear, the research suggests that drug-drug interactions in PI-based regimens may alter immunosuppression exposure, leading to potential toxicities. This article will explore the strengths and weaknesses of using SRTR data to guide the management of HIV-infected kidney transplant recipients, drawing upon the original research and other relevant studies.
Why the Topic Matters
HIV-associated kidney disease and end-stage kidney disease create complex clinical and policy challenges. Kidney transplantation can offer an important treatment option, but outcomes and access depend on factors including HIV management, immunosuppression, and transplant-center practices. Because these issues vary across patients and studies, SRTR findings should be interpreted with appropriate caution.
Multidisciplinary Transplant Care
Current guidance recommends a multidisciplinary team for people with HIV undergoing transplantation. The team may include nephrologists, hepatologists, hematologists, infectious disease and HIV specialists, transplant surgeons, pharmacists, nurses, and social workers. Kidney transplantation is now described as the standard of care for patients with HIV and end-stage kidney disease, although the complexity of care before, during, and after transplantation remains a significant limitation. (Reference URL 1; Reference URL 2)
From Contraindication to Standard Care
The history of transplantation in people with HIV reflects major advances in antiretroviral and transplant medicine. HIV-positive recipients historically experienced two- to fourfold higher rejection rates, while later trial and registry data confirmed that solid-organ transplantation can be effective in this population. Kidney transplantation has consequently become standard care for HIV-positive patients with end-stage renal disease. (Reference URL 1; Reference URL 2)
The Role of Protease Inhibitors and Their Impact on Transplant Outcomes
Protease inhibitors (PIs) have long been a cornerstone of HIV treatment, but their use in transplant recipients presents unique challenges. Several studies have indicated significantly higher rejection rates following kidney and liver transplantation in HIV-positive recipients, ranging from 30% to 40%. While this elevated rejection rate is partly due to immune dysregulation in HIV-infected individuals, PIs also play a significant role.
- Higher rejection rates: Studies show a 30-40% rejection rate in HIV-positive recipients post-transplant.
- CYP3A4 inhibition: Protease inhibitors disrupt the CYP3A4 system, affecting CNI dosing.
- CNI exposure variability: Poor CNI exposure leads to rejection; excessive levels cause toxicity.
Updated Evidence After HOPE
Recent reviews assess patient survival, graft survival, rejection, and infection rates after kidney transplantation in people living with HIV. The 2013 HIV Organ Policy Equity (HOPE) Act expanded eligibility for kidney transplantation in this population. One 2025 review reports that short-term patient and graft survival is comparable to that of HIV-negative recipients, while both decline after five years; it also reports graft rejection reaching 39% at five years and remaining higher than in HIV-negative recipients. (Reference URL 1; Reference URL 2)
Barriers to Listing
Failure to reach transplantation can occur during evaluation rather than after surgery. In one institutional analysis, 344 HIV-positive patients completed an initial kidney transplant evaluation, and 33 were declined for medical reasons. Reported reasons included active or recent malignancy in nine patients, persistent or anticipated failure to achieve viral suppression in six, and having no antiretroviral therapy in five. pmc.ncbi.nlm.nih.gov
Interpreting Group Comparisons
Comparisons between HIV-positive and HIV-negative kidney transplant recipients should account for changing treatment eras and differences in access to evaluation and listing. Apparent outcome gaps may reflect patient selection, comorbidities, immunosuppressive management, or historical changes in HIV therapy rather than HIV status alone. SRTR-based comparisons are therefore most useful when their populations, follow-up periods, and clinical context are clearly defined.
Moving Forward: Optimizing Care for HIV-Positive Transplant Recipients
The insights gained from SRTR data, despite its limitations, are invaluable in shaping the management of HIV-positive kidney transplant recipients. As Sawinski et al.'s analysis demonstrates, integrase-based cART regimens offer a promising alternative to PI-based regimens, reducing the risk of drug-drug interactions and improving overall outcomes. During pre-transplant evaluation, all HIV positive recipients should be evaluated by HIV/infectious disease specialists, who can determine if a switch to a non-Pl based cART is a feasible strategy. If a switch to a non-PI based regimen can safely be done based on resistance patterns, post-transplant management will be greatly facilitated by eliminating potentially dangerous drug-drug interactions. The ongoing efforts to refine data collection and analysis will undoubtedly contribute to further advancements in the field, ultimately enhancing the survival and quality of life for these vulnerable patients.
Emerging HIV-to-HIV Donation
Kidney transplantation from donors with HIV to recipients with HIV is an emerging practice. The 2024 New England Journal of Medicine report specifically examined the safety of this approach, while a January 2025 correspondence discussed the authors' findings and their interpretation. Together, these sources show that HIV-to-HIV kidney transplantation is an active area of clinical evaluation rather than an established conclusion that eliminates the need for careful monitoring. (Reference URL 1; Reference URL 2)
Expanding the Evidence Base
Future work will likely focus on longer-term graft and patient outcomes, rejection, infection, and the broader implementation of HIV-to-HIV transplantation. Continued research is needed to determine how newer antiretroviral regimens and transplant protocols affect outcomes over time. These developments may clarify how findings from specialized studies translate into routine transplant practice.
Access Beyond Eligibility
The central challenge is not only whether transplantation is medically possible, but also whether patients can complete evaluation and obtain access to listing. HIV-related end-stage kidney disease is disproportionately concentrated in minority populations, which can compound existing obstacles in the transplant process. Evaluating SRTR outcomes therefore requires attention to structural access, selection, and referral patterns as well as clinical outcomes.
Individual Decisions in Context
The human consequences of these issues are visible in individual clinical decisions. A 2019 case described a 49-year-old man with HIV infection and chronic kidney disease who was evaluated in a kidney transplantation clinic because his kidney function was declining. More recent work has examined whether long-term survival after kidney transplantation is comparable for recipients with and without HIV, while noting that older cohorts predated major advances such as integrase strand transferase inhibitors. (Reference URL 1; Reference URL 2)